Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | completed | Phase 4 | 34 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 16, 2026 | clinicaltrials |
| NCT04825574 | Study for Patients Previously Treated in Avapritinib Clinical Trials | completed | Phase 4 | 2 | Blueprint Medicines CorporationINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT00510354 | Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate(Radix) | completed | Phase 4 | 28 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02800330 | The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib(REGORA) | completed | Phase 4 | 31 | Erasmus Medical CenterOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT00171977 | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 4 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00777504 | Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | unknown | Phase 4 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 16, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials